Summit Therapeutics SMMT Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's restricted cash?
- Summit Therapeutics (SMMT) reported restricted cash of $316K in Q1 2026.
- How has Summit Therapeutics's restricted cash changed year-over-year?
- Summit Therapeutics's restricted cash decreased by 0.6% year-over-year, from $318K to $316K.
- What does restricted cash mean?
- Cash that is set aside for a specific purpose and cannot be used for general business operations.
- How do you interpret restricted cash?
- An increase may indicate new contractual obligations or collateral requirements, while a decrease suggests the release of restricted funds.
- How does restricted cash compare across companies?
- Common in companies with significant facility leases or debt financing arrangements.